Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with <sup>213</sup>Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.

导出 OA

翻译打印收藏纠错

作者： Andreas,Helisch ^[1] ; Clemens,Kratochwil ^[2] ; Christian,Kleist ^[3] ; Susanne,Krämer ^[3] ; Juan Jose,Rosales Castillo ^[4] ; Katharina,Dendl ^[3] ; Hendrik,Rathke ^[5] ; Isabelle,von Goetze ^[1] ; Mathias,Schreckenberger ^[1] ; Dirk,Jäger ^[6] ; Thomas,Lindner ^[7] ; Walter,Mier ^[3] ; Frederik,Giesel ^[8] ; Uwe,Haberkorn ^[9] ; Manuel,Röhrich ^[10]

作者单位： Department of Nuclear Medicine, University Medical Center, Mainz, Germany. ^[1] Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.;German Center of Lung Research, Heidelberg, Germany. ^[2] Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany. ^[3] Department of Nuclear Medicine, University Clinic of Navarra, Pamplona, Spain. ^[4] Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.;Department of Radiology, Cantonal Hospital Graubünden, Chur, Switzerland. ^[5] Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg, Germany. ^[6] Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.;Evergreen Theragnostics, Springfield, New Jersey. ^[7] Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.;Department of Nuclear Medicine, University Hospital, Düsseldorf, Germany; and. ^[8] Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.;German Center of Lung Research, Heidelberg, Germany.;Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany. ^[9] Department of Nuclear Medicine, University Medical Center, Mainz, Germany; manuel.roehrich@unimedizin-mainz.de.;Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.;German Center of Lung Research, Heidelberg, Germany. ^[10]

关键词 FAPI bismuth radiopharmaceutical therapy targeted therapy α-therapy